Changes of cytokines in the aqueous humor following Avastin intravitreous injection in early diabetic retinopathy rats

doi:10.3969/j.issn.2095-4344.2015.18.026

Abstract

Abstract:

BACKGROUND: Studies on the inhibitory mechanism of Avastin for early diabetic retinopathy rats are mostly confined to the vascular endothelial growth factor, while connective tissue growth factor and pigment epithelium-derived factor also play an important role in the disease.
OBJECTIVE: To evaluate the changed cytokines of aqueous humor and significance of Avastin intravitreous injection in early diabetic retinopathy rats.
METHODS: Rat models of early diabetic retinopathy were established by inducing with streptozotocin for 10 weeks. Avastin (1.25 mg and 2.5 mg) and physiological saline were injected in the vitreous space.
RESULTS AND CONCLUSION: Enzyme linked immunosorbent assay results revealed that compared with the physiological saline injection group, mass concentration of vascular endothelial growth factor was reduced, mass
concentrations of pigment epithelium-derived factor and connective tissue growth factor was increased in aqueous humor of the two Avastin injection groups (P < 0.05), but no significant difference in concentration of above cytokines was detected between the two groups (P > 0.05). Results verified that Avastin intravitreous injection decreased vascular endothelial growth factor levels, decreased pigment epithelium-derived factor mass concentration and increased connective tissue growth factor levels in rat models of early diabetic retinopathy.

中国组织工程研究杂志出版内容重点：肾移植；肝移植；移植；心脏移植；组织移植；皮肤移植；皮瓣移植；血管移植；器官移植；组织工程

全文链接：

Key words: Eye, Retinal Diseases, Diabetes Mellitus, Aqueous Humor, Cytokines

CLC Number:

R318

Xiao Jin-an, Bai Qing-yu, Xie An-ming. Changes of cytokines in the aqueous humor following Avastin intravitreous injection in early diabetic retinopathy rats[J]. Chinese Journal of Tissue Engineering Research, 2015, 19(18): 2933-2939.

Figures/Tables 1

References

[1] 许曼因.糖尿病学[M].上海:上海科学技术出版,2010.
[2] Roden M. Diabetes mellitus: Definition, classification and diagnosis. Wien Klin Wochenschr. 2012;124 Suppl 2:1-3.
[3] Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology. 1998;105(6):998-1003.
[4] Adamis AP, Altaweel M, Bressler NM, et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology. 2006;113(1):23-28.
[5] Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006;26(3):275-278.
[6] 玉高,吴晋晖,林柳.链脲佐菌素诱发性糖尿病大鼠早期视网膜病变模型的建立[J].第二军医大学学报,2010,31(10):1057- 1058.
[7] Manik S, Gauttam V, Kalia AN. Anti-diabetic and antihyperlipidemic effect of allopolyherbal formulation in OGTT and STZ-induced diabetic rat model. Indian J Exp Biol. 2013;51(9):702-708.
[8] Sinapis CI, Routsias JG, Sinapis AI, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin(R)) in rabbits. Clin Ophthalmol. 2007;5:697-704.
[9] 董宇,李松鹤,孙雅彬.金属锌对2型糖尿病大鼠模型视网膜病变的作用[J].中国实验诊断学2010;14(4):514-516.
[10] 石静丽,阚红卫,王海青.2型糖尿病大鼠视网膜病变模型的建立及羟苯磺酸钙的干预作用[J].中国实验方剂学杂志,2011,17(23): 181-183.
[11] Barzilay JI, Abraham L, Heckbert SR, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes. 2001;50(10):2384-2389.
[12] Chen J, Connor KM, Aderman CM, et al. Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest. 2008;118(2):526-533.
[13] Altintas AG, Arifoglu HB, Tutar E, Koklu G, Ozcan PY. Effect on anterior chamber bevacizumab injection combined with seton implantation in treatment of rubeosis iridis in neovascular glaucoma. Cutan Ocul Toxicol. 2012;31(2):124-127.
[14] Sugimoto Y, Mochizuki H, Okumichi H, et al. Effect of intravitreal bevacizumab on iris vessels in neovascular glaucoma patients. Graefes Arch Clin Exp Ophthalmol. 2010; 248(11):1601-1609.
[15] Yoon JU, Kim YM, Lee SJ, et al. Prognostic factors for visual outcome after intravitreal anti-VEGF injection for naive myopic choroidal neovascularization. Retina. 2012;32(5):949-955.
[16] Amano S, Yamagishi S, Inagaki Y, et al. Pigment epithelium-derived factor inhibits oxidative stress-induced apoptosis and dysfunction of cultured retinal pericytes. Microvasc Res. 2005;69(1-2):45-55.
[17] Yamagishi S, Matsui T, Nakamura K, et al. Pigment epithelium-derived factor (PEDF) prevents diabetes- or advanced glycation end products (AGE)-elicited retinal leukostasis. Microvasc Res. 2006;72(1-2):86-90.
[18] Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science. 1999;285(5425):245-248.
[19] Tombran-Tink J, Shivaram SM, Chader GJ, et al. Expression, secretion, and age-related downregulation of pigment epithelium-derived factor, a serpin with neurotrophic activity. J Neurosci. 1995;15(7 Pt 1):4992-5003.
[20] Wu YQ, Notario V, Chader GJ, et al. Identification of pigment epithelium-derived factor in the interphotoreceptor matrix of bovine eyes. Protein Expr Purif. 1995;6(4):447-456.
[21] Perez-Mediavilla LA, Chew C, Campochiaro PA, et al. Sequence and expression analysis of bovine pigment epithelium-derived factor. Biochim Biophys Acta. 1998; 1398(2): 203-214.
[22] Karakousis PC, John SK, Behling KC, et al. Localization of pigment epithelium derived factor (PEDF) in developing and adult human ocular tissues. Mol Vis. 2001;7:154-163.
[23] Ogata N, Wada M, Otsuji T, et al. Expression of pigment epithelium-derived factor in normal adult rat eye and experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2002;43(4):1168-1175.
[24] Bouck N. PEDF: anti-angiogenic guardian of ocular function. Trends Mol Med. 2002;8(7):330-734.
[25] Ogata N, Tombran-Tink J, Nishikawa M, et al. Pigment epithelium-derived factor in the vitreous is low in diabetic retinopathy and high in rhegmatogenous retinal detachment. Am J Ophthalmol. 2001;132(3):378-382.
[26] Cao W, Tombran-Tink J, Elias R, et al. In vivo protection of photoreceptors from light damage by pigment epithelium- derived factor. Invest Ophthalmol Vis Sci. 2001; 42(7): 1646-1652.
[27] Shi-Wen X, Leask A, Abraham D. Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis. Cytokine Growth Factor Rev. 2008;19(2): 133-144.
[28] Lasky JA, Ortiz LA, Tonthat B, et al. Connective tissue growth factor mRNA expression is upregulated in bleomycin-induced lung fibrosis. Am J Physiol. 1998;275(2 Pt 1):L365-L371.
[29] Braig S, Wallner S, Junglas B, et al. CTGF is overexpressed in malignant melanoma and promotes cell invasion and migration. Br J Cancer. 2011;105(2):231-238.
[30] Babic AM, Chen CC, Lau LF. Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin alphavbeta3, promotes endothelial cell survival, and induces angiogenesis in vivo. Mol Cell Biol. 1999;19(4):2958-2966.
[31] Zhang B, Zhou KK, Ma JX. Inhibition of connective tissue growth factor overexpression in diabetic retinopathy by SERPINA3K via blocking the WNT/beta-catenin pathway. Diabetes;59(7):1809-1816.
[32] 刘鹏飞,惠延年,谢小萍.促红细胞生成素受体抗体抑制小鼠视网膜新生血管形成[J].国际眼科杂志,2008,8(3):507-509.
[33] Inoki I, Shiomi T, Hashimoto G, et al. Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. Faseb J. 2002; 16(2):219-221.
[34] Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 1999;85(3):221-228.
[35] Bourcier T, Berbar T, Paquet S, et al. Characterization and functionality of CXCR4 chemokine receptor and SDF-1 in human corneal fibroblasts. Mol Vis. 2003;9:96-102.
[36] Yamaguchi J, Kusano KF, Masuo O, et al. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation. 2003;107(9):1322-1328.
[37] Cohen AF, van Bronswijk H. New medications; bevacizumab. Ned Tijdschr Geneeskd. 2006;150(40):2194-2195.
[38] Kahook MY, Schuman JS, Noecker RJ. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging. 2006;37(2):144-146.
[39] Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112(6):1035- 1047.
[40] Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina. 2006;26(3):354-356.
[41] Batioglu F, Astam N, Ozmert E. Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma. Int Ophthalmol. 2008; 28(1):59-61.
[42] Arevalo JF, Garcia-Amaris RA. Intravitreal bevacizumab for diabetic retinopathy. Curr Diabetes Rev. 2009;5(1):39-46.
[43] 周云燕,张仁俊.Avastin联合曲安奈德玻璃体腔注射治疗糖尿病视网膜病变伴黄斑水肿[J].国际眼科杂志,2010,10(3):475-476.
[44] Yang CM, Yeh PT, Yang CH, et al. Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy. Am J Ophthalmol. 2008;146(2):211-217.
[45] Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina. 2006; 26(5):495-511